Show simple item record

dc.contributor.authorHahne, JC
dc.contributor.authorValeri, N
dc.date.accessioned2018-06-11T08:26:51Z
dc.date.accessioned2018-06-11T09:04:26Z
dc.date.issued2018-06-18
dc.identifier.citationFrontiers in oncology, 2018, 8 pp. 226 - ?
dc.identifier.issn2234-943X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1785
dc.identifier.eissn2234-943X
dc.identifier.doi10.3389/fonc.2018.00226
dc.description.abstractNon-coding RNAs are important regulators of gene expression and transcription. It is well established that impaired non-coding RNA expression especially the one of long non-coding RNAs and microRNAs is involved in a number of pathological conditions including cancer. Non-coding RNAs are responsible for the development of resistance to anticancer treatments as they regulate drug resistance-related genes, affect intracellular drug concentrations, induce alternative signaling pathways, alter drug efficiency via blocking cell cycle regulation, and DNA damage response. Furthermore, they can prevent therapeutic-induced cell death and promote epithelial-mesenchymal transition (EMT) and elicit non-cell autonomous mechanisms of resistance. In this review, we summarize the role of non-coding RNAs for different mechanisms resulting in drug resistance (e.g., drug transport, drug metabolism, cell cycle regulation, regulation of apoptotic pathways, cancer stem cells, and EMT) in the context of gastrointestinal cancers.
dc.formatElectronic-eCollection
dc.format.extent226 - ?
dc.languageeng
dc.language.isoeng
dc.publisherFRONTIERS MEDIA SA
dc.relation.replaceshttps://repository.icr.ac.uk/handle/internal/1781
dc.relation.replacesinternal/1781
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleNon-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors.
dc.typeJournal Article
dcterms.dateAccepted2018-05-31
rioxxterms.versionofrecord10.3389/fonc.2018.00226
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfFrontiers in oncology
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.publication-statusPublished
pubs.volume8
pubs.embargo.termsNot known
icr.researchteamGastrointestinal Cancer Biology and Genomics
dc.contributor.icrauthorHahne, Jens
dc.contributor.icrauthorValeri, Nicola


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0